Aviva’s Maravai LifeSciences MRVI Stock Holding History

Aviva’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-64,565	Closed	-$1.83M	–	1042
2022 Q2	$1.83M	Buy	+64,565	New	+$2.05M	0.01%	879

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Aviva's MRVI Position: Q3 2022 in Review

Aviva sold out of Maravai LifeSciences (MRVI) in Q3 2022, closing a stake of 64,565 shares — an estimated $1.83M sold.

Aviva first reported a position in MRVI in Q2 2022 and held it in 1 quarter. The position peaked at $1.83M in Q2 2022. 202 funds tracked by Wall St. Rank hold MRVI as of Q3 2022.

Aviva reported no remaining Maravai LifeSciences position as of Q3 2022 after selling out during the quarter.
Aviva sold 64,565 Maravai LifeSciences shares in Q3 2022, an estimated $1.83M.
Aviva first reported a position in Maravai LifeSciences in Q2 2022 and held it in 1 quarter.
Aviva's Maravai LifeSciences position peaked at $1.83M in Q2 2022.
202 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2022.

Based on Aviva's 13F filing for Q3 2022, filed 14 Nov 2022.